KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

West Pharmaceutical Services (WST) Equity Income (2016 - 2025)

Historic Equity Income for West Pharmaceutical Services (WST) over the last 17 years, with Q4 2025 value amounting to $3.9 million.

  • West Pharmaceutical Services' Equity Income rose 9500.0% to $3.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $14.4 million, marking a year-over-year decrease of 204.08%. This contributed to the annual value of $14.4 million for FY2025, which is 204.08% down from last year.
  • According to the latest figures from Q4 2025, West Pharmaceutical Services' Equity Income is $3.9 million, which was up 9500.0% from $2.1 million recorded in Q3 2025.
  • West Pharmaceutical Services' Equity Income's 5-year high stood at $8.6 million during Q2 2021, with a 5-year trough of $2.0 million in Q4 2024.
  • Its 5-year average for Equity Income is $4.6 million, with a median of $4.5 million in 2024.
  • Over the last 5 years, West Pharmaceutical Services' Equity Income had its largest YoY gain of 9500.0% in 2025, and its largest YoY loss of 4615.38% in 2025.
  • Over the past 5 years, West Pharmaceutical Services' Equity Income (Quarter) stood at $6.5 million in 2021, then crashed by 50.77% to $3.2 million in 2022, then rose by 3.12% to $3.3 million in 2023, then plummeted by 39.39% to $2.0 million in 2024, then surged by 95.0% to $3.9 million in 2025.
  • Its last three reported values are $3.9 million in Q4 2025, $2.1 million for Q3 2025, and $5.0 million during Q2 2025.